What Is A Diagnostic Smart Pad, And Can It Track Your Hormones At Home?

The pitch is straightforward: a menstrual pad that runs a hormone test while you use it – no lab visit, no extra steps, no separate device.

At roughly $4 to $5 per pad, the FlowPad by Vivoo is the first product to bring diagnostic capability into something women are already buying. It was unveiled at CES 2026, and whether or not it reaches mass market, the idea it represents is one of the more interesting distribution strategies to emerge from femtech in years.

The concept is a diagnostic smart pad – a menstrual pad with a microfluidic diagnostic layer built in that analyses menstrual blood and vaginal fluids for biological markers. The FlowPad’s layer contains stabilised reagents that react with specific markers to produce colour changes, which are read either directly from a transparent window in the pad or by scanning it with the Vivoo smartphone app. The app’s image processing evaluates the hue shifts and reaction intensities to produce a personalised analysis – no Bluetooth, no sensors, no charging.

The markers it tracks include follicle-stimulating hormone for fertility tracking, ovulation signals, pH imbalances, infection indicators, amniotic fluid leakage in pregnancy and sexually transmitted disease markers. A subscription is required for the detailed app analysis. The product was revealed as a conceptual product at CES 2026, with clinical validation status and availability not yet confirmed in public reports.

The Smarter Play Is In The Distribution

While the FlowPad’s underlying technology is impressive, its true value lies in its positioning.

Women’s health diagnostics have traditionally required an additional step: a separate test, a clinic appointment, a device to remember to use. The FlowPad’s approach – embedding the diagnostic into a product that’s already part of a routine – removes that friction. The test happens as a byproduct of something that was happening anyway.

This approach to distribution is emerging as a trend across the femtech industry. Period tracking moved from a standalone app category into features embedded inside general health platforms and smartwatches. Fertility monitoring moved from clinic-only tests to at-home ovulation kits, then to wearables worn overnight. Each step lowers the barrier to data access. Diagnostic smart pads are the next iteration of that pattern: the product you already buy becomes the test.

The potential to transform health data access is substantial. Hormone tracking, fertility awareness and early infection detection are all conditions where earlier, more frequent information changes outcomes – but where the barriers to regular testing have historically been high.

A pad that produces a hormone reading as a side effect of normal use closes that access problem differently from a wearable or an app. It reaches people who aren’t looking to track their health, because the product does it without them having to decide to.

Before This Goes Mainstream, Ask These Questions

That brings us to the most important question: how does it hold up under clinical validation?

Colour-change reagent tests are well-established – pregnancy tests and COVID-19 lateral flow tests use the same basic principle – but applying that to a broader panel of hormones and infection markers via a smartphone camera scan introduces variables that lab-grade tests don’t have. Lighting conditions, camera quality, scan angle and the consistency of the reagent layer under real-world conditions all affect accuracy. Until clinical data exists, the FlowPad is a promising concept rather than a validated diagnostic tool.

The data privacy question is the other one. Menstrual and reproductive health data is among the most sensitive categories of personal health information, particularly in jurisdictions where reproductive rights are contested. A product that collects hormone and fertility data via a smartphone app, stored on a subscription platform, is a product with a data governance model that deserves scrutiny. The femtech sector as a whole is still developing its norms around this.

The concept remains sound: layering diagnostics into a low-cost, widely used product completely changes the game for women’s health data. Should the clinical validation follow, this will be one of the most significant and actionable femtech innovations of the last decade.